NCT07621718Phase 3Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Study sponsor: Revolution Medicines, Inc. · RVMD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-12-30Estimated

Enrollment · participants670Estimated

Source updated2026-09-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma

Treatments or interventions studied

ZoldonrasibDrug
PlaceboDrug
OxaliplatinDrug
Leucovorin (Calcium Folinate)Drug
5-FluorouracilDrug
IrinotecanDrug
Gemcitabine (GEM)Drug
Nab-paclitaxelDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression free survival (PFS); description: PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed per response evaluation criteria in solid tumors (RECIST) v1.1 by Investigator.; timeFrame: Up to approximately 4 years; measure: Overall survival (OS); description: OS is defined as the time from randomization until death from any cause.; timeFrame: Up to approximately 4 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history